Vasculitis & polymyalgia rheumatica

Efficacy and safety of leflunomide in the management of large vessel vasculitis: A systematic review and metaanalysis of cohort studies

Semin Arthritis RheumPublished Systematic review and meta-analysis of cohort studies

Authors' conclusion

LEF is well tolerated and might be effective for patients with TAK and GCA.

Study context

Population
Patients with large vessel vasculitis (LVV) (Takayasu arteritis and giant cell arteritis (GCA)) treated with leflunomide8 studies TAK, 7 GCA
Comparison
TAK vs GCA
Outcome
Efficacy (remission) and safety of LEF in LVV
Methodological detailsrandom-effects meta-analysis, uncontrolled observational studies
  • Random-effects meta-analysis
  • Uncontrolled observational studies

Pooled result

As reported in the abstract

At least partial remission (pooled proportion)

Further pooled results

Angiographic stabilization in TAK, pooled proportion

TAK: angiographic stabilization
86% (0.77-0.94)

Relapses in TAK, pooled proportion

TAK: relapses
12% (0.05-0.21)

Mean reduction in prednisolone dose (mean reduction in the prednisolone dose (MRPD)) after leflunomide (LEF) in TAK

TAK: MRPD
15.7 mg/d (10.28-21.16)

LEF vs methotrexate (MTX) or cyclophosphamide in TAK

LEF superior in remission induction, relapse prevention and tolerance

LEF vs tofacitinib in TAK

Comparable efficacy

MRPD after LEF in GCA

GCA: MRPD
15.63 mg/d (1.29-32.55)

GC discontinuation in GCA, pooled proportion

GCA: able to discontinue GC
53% (0.25 - 0.80)

Relapses in GCA, pooled proportion of cases

GCA: relapses
21% (0.14- 0.28)

LEF vs MTX in GCA

Similar efficacy and tolerance

Safety

Adverse events in TAK, pooled proportion of patients

TAK: adverse events
8% (0.02-0.16)

Adverse events in GCA, pooled proportion

GCA: adverse events
28% (0.12-0.46)

Original publication

Efficacy and safety of leflunomide in the management of large vessel vasculitis: A systematic review and metaanalysis of cohort studies. Semin Arthritis Rheum. Published 11 January 2023. doi:10.1016/j.semarthrit.2023.152166

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.